Clinical Research Organization, Dhaka, Bangladesh Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01374308
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

sorafenib (nexavar) (1 trial)

Drugs in Phase 2 Trials (1)

oncoxin-viusid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4